Literature DB >> 23175543

Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images.

Azusa Kitao1, Osamu Matsui, Norihide Yoneda, Kazuto Kozaka, Satoshi Kobayashi, Wataru Koda, Toshifumi Gabata, Tatsuya Yamashita, Shuichi Kaneko, Yasuni Nakanuma, Ryuichi Kita, Shigeki Arii.   

Abstract

PURPOSE: To analyze the correlation among biologic features, tumor marker production, and signal intensity at gadoxetic acid-enhanced MR imaging in hepatocellular carcinomas (HCCs).
MATERIALS AND METHODS: Institutional ethics committee approval and informed consent were obtained for this retrospective study. From April 2008 to September 2011, 180 surgically resected HCCs in 180 patients (age, 65.0 years ± 10.3 [range, 34-83 years]; 138 men, 42 women) were classified as either hypointense (n = 158) or hyperintense (n = 22) compared with the signal intensity of the background liver on hepatobiliary phase gadoxetic acid-enhanced MR images. Pathologic features were analyzed and a fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) production were compared by means of serum analysis and immunohistochemical staining. Recurrence and survival rates were also evaluated. The Mann-Whitney and Pearson correlation tests were used for statistical analysis.
RESULTS: The grade of differentiation was higher (P = .028) and portal vein invasion was less frequent in hyperintense HCCs (13.6%) than in hypointense HCCs (36.7%) (P = .039). The serum levels of AFP, Lens culinaris agglutinin reactive fraction of AFP, and PIVKA-II were lower in hyperintense than in hypointense HCCs (P = .003, .004, and .026, respectively). Immunohistochemical AFP and PIVKA-II expression were lower in hyperintense than in hypointense HCCs (both P < .001). The recurrence rate was lower in hyperintense than in hypointense HCCs (P = .039).
CONCLUSION: The results suggest that hyperintense HCCs on gadoxetic acid-enhanced MR images are less aggressive than hypointense HCCs. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.12120226/-/DC1. © RSNA, 2012.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23175543      PMCID: PMC5375624          DOI: 10.1148/radiol.12120226

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  22 in total

1.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

2.  Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production.

Authors:  Yoshiki Asayama; Tsuyoshi Tajima; Akihiro Nishie; Kousei Ishigami; Daisuke Kakihara; Tomohiro Nakayama; Daisuke Okamoto; Nobuhiro Fujita; Shinichi Aishima; Ken Shirabe; Hiroshi Honda
Journal:  Eur J Radiol       Date:  2010-11-24       Impact factor: 3.528

3.  Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

Authors:  Sung Soo Ahn; Myeong-Jin Kim; Joon Seok Lim; Hye-Suk Hong; Yong Eun Chung; Jin-Young Choi
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

4.  Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.

Authors:  Azusa Kitao; Yoh Zen; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Kazuto Kozaka; Norihide Yoneda; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

Review 5.  The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology.

Authors:  Stephen Caldwell; Sang H Park
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

6.  Functional mapping of tissue-specific elements of the human alpha-fetoprotein gene enhancer.

Authors:  Hidekazu Nakabayashi; Yoshikazu Koyama; Hiroshi Suzuki; Hong Mei Li; Masaharu Sakai; Yutaka Miura; Norman C W Wong; Shinzo Nishi
Journal:  Biochem Biophys Res Commun       Date:  2004-06-04       Impact factor: 3.575

7.  The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma.

Authors:  Stephan R Vavricka; Diana Jung; Michael Fried; Uwe Grützner; Peter J Meier; Gerd A Kullak-Ublick
Journal:  J Hepatol       Date:  2004-02       Impact factor: 25.083

8.  Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis.

Authors:  Shigeru Saito; Hidenori Ojima; Hitoshi Ichikawa; Setsuo Hirohashi; Tadashi Kondo
Journal:  Cancer Sci       Date:  2008-11-24       Impact factor: 6.716

9.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

Authors:  Taro Yamashita; Marshonna Forgues; Wei Wang; Jin Woo Kim; Qinghai Ye; Huliang Jia; Anuradha Budhu; Krista A Zanetti; Yidong Chen; Lun-Xiu Qin; Zhao-You Tang; Xin Wei Wang
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

Review 10.  Des-gamma-carboxyprothrombin: clinical effectiveness and biochemical importance.

Authors:  Yoshinori Inagaki; Wei Tang; Huanli Xu; Fengshan Wang; Munehiro Nakata; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Biosci Trends       Date:  2008-04       Impact factor: 2.400

View more
  47 in total

1.  Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging.

Authors:  Nobuhiro Fujita; Akihiro Nishie; Yuichiro Kubo; Yoshiki Asayama; Yasuhiro Ushijima; Yukihisa Takayama; Koichiro Moirta; Ken Shirabe; Shinichi Aishima; Hiroshi Honda
Journal:  Eur Radiol       Date:  2014-07-26       Impact factor: 5.315

2.  Doughnut-like hyperintense nodules on hepatobiliary phase without arterial-phase hyperenhancement in cirrhotic liver: imaging and clinicopathological features.

Authors:  Kazuto Kozaka; Satoshi Kobayashi; Norihide Yoneda; Azusa Kitao; Kotaro Yoshida; Dai Inoue; Takahiro Ogi; Wataru Koda; Yasunori Sato; Toshifumi Gabata; Osamu Matsui
Journal:  Eur Radiol       Date:  2019-07-05       Impact factor: 5.315

Review 3.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 4.  Hepatocyte-specific contrast media: not so simple.

Authors:  Andrew T Trout; Alexander J Towbin; Ethan A Smith; Anita Gupta; Jonathan R Dillman
Journal:  Pediatr Radiol       Date:  2018-08-04

Review 5.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

Review 6.  Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid.

Authors:  Francesco Agnello; Marco Dioguardi Burgio; Dario Picone; Federica Vernuccio; Giuseppe Cabibbo; Lydia Giannitrapani; Adele Taibbi; Antonino Agrusa; Tommaso Vincenzo Bartolotta; Massimo Galia; Roberto Lagalla; Massimo Midiri; Giuseppe Brancatelli
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 7.  Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI.

Authors:  Alexander Kagen; Kathryn Fowler; Claude B Sirlin
Journal:  Hepat Oncol       Date:  2013-12-20

Review 8.  Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma.

Authors:  Norihide Yoneda; Osamu Matsui; Satoshi Kobayashi; Azusa Kitao; Kazuto Kozaka; Dai Inoue; Kotaro Yoshida; Tetsuya Minami; Wataru Koda; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2019-02-02       Impact factor: 2.374

9.  Breakthrough Imaging in Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

Review 10.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.